Alphamab Oncology's high P/S ratio may not be justified due ...
Alphamab Oncology's high P/S ratio may not be justified due to weak revenue forecasts. Investors should remain cautious as this could negatively impact the share price.
Alphamab Oncology's (HKG:9966) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment